| Management target | Revenue 25.0% FY32 |
|---|
| Revenue growth | 16.5% YoY growth to ₹211.6 Cr, almost entirely organic. |
|---|---|
| Margins | Gross margins expanded 260 bps despite geopolitical supply chain headwinds. |
| Order book | Strong order pipeline for recently acquired API entities and CDMO projects. |
| Demand visibility | Strong domestic prescription demand; international business returning to growth path. |
| Management confidence | Balanced and disciplined, focusing on volume-led growth and integration synergies. |
Growth
Revenue grew 16.5% YoY, primarily organic. Domestic formulations volume grew 6.8%, nearly double the market rate.
Outlook
Targeting 25% CAGR in API business and ₹25 Cr R&D investment by FY30.
Risks
West Asia conflict impacting logistics and input costs; high employee expense growth from fixed-labor conversion.
Earnings Call Transcript filed with NSE, NSE: RPGLIFE. Summary written with AI assistance from the document.
RPG Life Sciences Ltd: key numbers
- Share price
- ₹2,575.70
- Market cap
- ₹4,260 Cr
- Revenue (annual)
- ₹707.5 Cr
- Net profit (annual)
- ₹115.2 Cr
- P/E (TTM)
- 38.9×Sector 45.9×
- Promoter holding
- 72.95%+0.00% QoQ
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from RPG Life Sciences Ltd
All →RPG Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹211.6 cr (+16.5%), adj PAT ₹32.3 cr (+13.4%), PAT margin 15.3%. API sales up 89%; domestic formulations +11.6%, international +6.4%.
RPG Life Sciences Results Update
RPG Life Sciences reported Q2 FY27 revenue of ₹211.6 crore, growing 16.5%, and adjusted EBITDA of ₹50.1 crore. The API business integration continues to progress.
RPG Life Sciences Q2 FY27 Results: Net Profit ₹28.2 Cr, Down 23.6% YoY
RPG Life Sciences Ltd reported revenue from operations of ₹211.6 Cr (+16.5% YoY) and net profit of ₹28.2 Cr (-23.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹28.2 Cr · -23.6% YoY
RPG Life Sciences Board Meeting Date
RPG Life Sciences Limited has scheduled a board meeting on October 29, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.
RPG Life Sciences Other Announcement
This is the quarterly shareholding pattern filing for RPG Life Sciences Ltd for the quarter ended September 30, 2026.
RPG Life Sciences Capital Structure Change
Clarus Trust acquired 37,463 shares of RPG Life Sciences through an open market transaction. This acquisition increases the acquirer's total stake to 7.04%.